PortfoliosLab logo
SRPT vs. DAVE
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SRPT and DAVE is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Performance

SRPT vs. DAVE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sarepta Therapeutics, Inc. (SRPT) and Dave Inc. (DAVE). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Sharpe Ratio

SRPT:

-1.04

DAVE:

2.74

Sortino Ratio

SRPT:

-1.89

DAVE:

3.41

Omega Ratio

SRPT:

0.70

DAVE:

1.43

Calmar Ratio

SRPT:

-0.90

DAVE:

2.97

Martin Ratio

SRPT:

-2.11

DAVE:

12.90

Ulcer Index

SRPT:

34.41%

DAVE:

21.53%

Daily Std Dev

SRPT:

70.08%

DAVE:

100.12%

Max Drawdown

SRPT:

-98.17%

DAVE:

-99.01%

Current Drawdown

SRPT:

-79.62%

DAVE:

-59.47%

Fundamentals

Market Cap

SRPT:

$3.58B

DAVE:

$2.47B

EPS

SRPT:

-$2.64

DAVE:

$3.56

PS Ratio

SRPT:

1.60

DAVE:

6.49

PB Ratio

SRPT:

3.13

DAVE:

12.40

Total Revenue (TTM)

SRPT:

$2.23B

DAVE:

$371.30M

Gross Profit (TTM)

SRPT:

$1.81B

DAVE:

$269.46M

EBITDA (TTM)

SRPT:

-$117.73M

DAVE:

$58.71M

Returns By Period

In the year-to-date period, SRPT achieves a -70.04% return, which is significantly lower than DAVE's 113.36% return.


SRPT

YTD

-70.04%

1M

-32.27%

6M

-65.15%

1Y

-72.27%

3Y*

-19.40%

5Y*

-24.27%

10Y*

4.16%

DAVE

YTD

113.36%

1M

120.07%

6M

131.64%

1Y

272.17%

3Y*

36.02%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Sarepta Therapeutics, Inc.

Dave Inc.

Risk-Adjusted Performance

SRPT vs. DAVE — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SRPT
The Risk-Adjusted Performance Rank of SRPT is 22
Overall Rank
The Sharpe Ratio Rank of SRPT is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of SRPT is 33
Sortino Ratio Rank
The Omega Ratio Rank of SRPT is 22
Omega Ratio Rank
The Calmar Ratio Rank of SRPT is 22
Calmar Ratio Rank
The Martin Ratio Rank of SRPT is 00
Martin Ratio Rank

DAVE
The Risk-Adjusted Performance Rank of DAVE is 9696
Overall Rank
The Sharpe Ratio Rank of DAVE is 9898
Sharpe Ratio Rank
The Sortino Ratio Rank of DAVE is 9696
Sortino Ratio Rank
The Omega Ratio Rank of DAVE is 9595
Omega Ratio Rank
The Calmar Ratio Rank of DAVE is 9696
Calmar Ratio Rank
The Martin Ratio Rank of DAVE is 9797
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SRPT vs. DAVE - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and Dave Inc. (DAVE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The current SRPT Sharpe Ratio is -1.04, which is lower than the DAVE Sharpe Ratio of 2.74. The chart below compares the historical Sharpe Ratios of SRPT and DAVE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading data...

Dividends

SRPT vs. DAVE - Dividend Comparison

Neither SRPT nor DAVE has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SRPT vs. DAVE - Drawdown Comparison

The maximum SRPT drawdown since its inception was -98.17%, roughly equal to the maximum DAVE drawdown of -99.01%. Use the drawdown chart below to compare losses from any high point for SRPT and DAVE. For additional features, visit the drawdowns tool.


Loading data...

Volatility

SRPT vs. DAVE - Volatility Comparison

Sarepta Therapeutics, Inc. (SRPT) has a higher volatility of 40.56% compared to Dave Inc. (DAVE) at 35.12%. This indicates that SRPT's price experiences larger fluctuations and is considered to be riskier than DAVE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading data...

Financials

SRPT vs. DAVE - Financials Comparison

This section allows you to compare key financial metrics between Sarepta Therapeutics, Inc. and Dave Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M20212022202320242025
744.86M
97.85M
(SRPT) Total Revenue
(DAVE) Total Revenue
Values in USD except per share items

SRPT vs. DAVE - Profitability Comparison

The chart below illustrates the profitability comparison between Sarepta Therapeutics, Inc. and Dave Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%70.0%80.0%90.0%20212022202320242025
81.5%
71.9%
(SRPT) Gross Margin
(DAVE) Gross Margin
SRPT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported a gross profit of 607.29M and revenue of 744.86M. Therefore, the gross margin over that period was 81.5%.

DAVE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Dave Inc. reported a gross profit of 70.34M and revenue of 97.85M. Therefore, the gross margin over that period was 71.9%.

SRPT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported an operating income of -300.39M and revenue of 744.86M, resulting in an operating margin of -40.3%.

DAVE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Dave Inc. reported an operating income of 25.02M and revenue of 97.85M, resulting in an operating margin of 25.6%.

SRPT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported a net income of -447.51M and revenue of 744.86M, resulting in a net margin of -60.1%.

DAVE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Dave Inc. reported a net income of 28.81M and revenue of 97.85M, resulting in a net margin of 29.4%.